ClinicalTrials.gg
Not yet recruitingNCT07538258Aurora004Updated Apr 20, 2026

Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer

A Phase 2 interventional study of Benmelstobart and Anlotinib in Limited-stage Small Cell Lung Cancer (LS-SCLC), sponsored by Yayi He. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Yayi He · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing benmelstobart in Small Cell Lung Carcinoma — 8 open to participants now, 8 under way, 2 of them phase 3. benmelstobart · Small Cell Lung Carcinoma.

Planned enrollment
9th of 10
27 · median 45
Started
2026
with 2 others
Phase 2
5 of 10
4 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Yayi He

Among the 10 studies testing benmelstobart in Small Cell Lung Carcinoma, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 8th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 10 studies testing benmelstobart in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing benmelstobart in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a single-arm, single-center, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. The study evaluates the effectiveness and safety of first-line treatment with benmelstobart (an immunotherapy), anlotinib (an anti-angiogenic drug), platinum-etoposide chemotherapy, and concurrent thoracic radiotherapy in participants with previously untreated, unresectable limited-stage small cell lung cancer (LS-SCLC).

Eligible participants are aged 18 to 75 years, with histologically or cytologically confirmed limited-stage SCLC (VALG staging), no prior systemic treatment for lung cancer, measurable lesions by RECIST 1.1, ECOG performance status 0-1, and adequate organ function.

Participants receive 4 cycles of induction therapy (21 days per cycle), including benmelstobart intravenously every 3 weeks, anlotinib orally for 2 weeks on / 1 week off, and chemotherapy with carboplatin or cisplatin plus etoposide. Thoracic radiotherapy (60-70 Gy in 30-35 fractions) is given concurrently with chemotherapy cycles 1-3. After induction, participants receive maintenance therapy with benmelstobart plus anlotinib for up to 2 years or until disease progression or unacceptable side effects.

The primary objective is to assess the Objective Response Rate (ORR) as evaluated by investigators using RECIST 1.1. Secondary objectives include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), and safety assessments of adverse events graded by CTCAE 5.0.

A total of 27 participants will be enrolled. The study is expected to start in March 2026, complete enrollment by September 2027, and end in March 2029. All participants will be regularly followed for efficacy and safety.

03

Conditions studied

  • Limited-stage Small Cell Lung Cancer (LS-SCLC)

Keywords

  • Limited-stage small cell lung cancer
  • benmelstobart
  • anlotinib
  • chemotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1: or cytologically confirmed inoperable limited-stage small cell lung cancer (LS-SCLC) (per VALG staging).

    2: No prior systemic therapy for limited-stage small cell lung cancer

    3: Presence of as defined by 1.1. A previously irradiated lesion may be considered measurable only if it has demonstrated clear progression after radiotherapy and is not the sole lesion

    4: Age ≥ 18 and ≤ 75 years

    5: performance status: 0-1

    6: Expected survival ≥ 3 months

    7: Adequate hematologic and organ function, defined as meeting the following criteria: a) Hematologic function (no transfusion of blood or blood products, no G-CSF or other hematopoietic growth factors within 14 days): i. (ANC) ≥ 1.5 × 10⁹/L (1,500/mm³); ii. count (PLT) ≥ 100 × 10⁹/L (100,000/mm³); iii. (HB) ≥ 80 g/L. b) Renal function: i. Calculated (CrCl) ≥ 50 mL/min; ii. Urine protein \< 2+ or 24-hour urine protein quantification \< 1.0 g. c) Hepatic function: i. Serum total (TBil) ≤ 1.5 × ; ii. and ALT ≤ 2.5 × ULN; iii. Serum albumin (ALB) ≥ 28 g/L. d) Coagulation function: i. (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. e) Cardiac function: i. (LVEF) ≥ 50%.

    8: Subjects voluntarily participate in this study, provide written , demonstrate good compliance, and agree to comply with follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  • 1: Prior use of anti-angiogenic agents such as anlotinib, apatinib, bevacizumab, or related immunotherapeutic agents targeting , PD-L1, etc

    2: Presence of multiple factors affecting oral medication absorption (e.g., inability to swallow, status post gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.).

    3: Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.

    4: Patients with imaging evidence of tumor invasion adjacent to major blood vessels, or judged by the investigator to have a high risk of fatal massive hemorrhage due to tumor invasion of major blood vessels during the subsequent study period.

    5: History of severe bleeding tendency or coagulopathy, including but not limited to: hemoptysis (more than one tablespoon per day) within 3 months prior to enrollment; or clinically significant bleeding symptoms or bleeding diathesis within 4 weeks prior to randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer (including gastrointestinal perforation and/or fistula; however, patients with surgically repaired gastrointestinal perforation or fistula may be eligible), unhealed wounds, ulcers, or fractures, etc.

    6: Undergoing major surgical treatment, incisional , or significant traumatic injury within 28 days prior to randomization.

    7: History of arterial/venous thrombotic events within 6 months prior to randomization, such as cerebrovascular accident (including ), deep vein thrombosis, and pulmonary embolism.

    8: Development of active disease requiring systemic therapy (e.g., disease-modifying agents, , or ) within 2 years prior to the first dose.

    9: Any other conditions that, in the judgment of the investigator, would render the patient ineligible for study enrollment.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Benmelstobart combined with anlotinib and chemotherapy concurrent with thoracic radiotherapy

    Benmelstobart combined with anlotinib plus chemotherapy concurrent with thoracic radiotherapy for limited-stage small cell lung cancer. Benmelstobart Injection: 1200 mg/dose, Q21D (1 cycle), IV infusion. Anlotinib Hydrochloride Capsules: 12 mg/day, oral (2 weeks on/1 week off, repeated Q3W), taken with water at fixed time. Chemotherapy: Carboplatin: Day 1, AUC 5 mg/mL/min (max 750 mg), IV infusion; Cisplatin: Day 1, 75-80 mg/m², IV infusion; Etoposide: Days 1-3, 100 mg/m², IV infusion. Concurrent Thoracic Radiation: Initiated with Cycle 1 of chemotherapy; IMRT, 60-70 Gy in 30-35 fractions (1.8-2.0 Gy/fraction, once daily); target volumes: primary tumor + lymph nodes delineated on post-chemotherapy CT, investigator-adjusted individually.

    Drug: Benmelstobart · Drug: Anlotinib · Drug: Cisplatin or carboplatin · Drug: Etoposide · Radiation: Thoracic Radiation Therapy

Interventions

  • Anti-PD-L1 monoclonal antibody, immunotherapy.1200 mg/dose, Q21D (1 cycle), IV infusion.

    Also known as: TQB2450, Andewei

  • Small molecule multi-target anti-angiogenic agent.12 mg/day, oral (2 weeks on/1 week off, repeated Q3W), taken with water at fixed time.

    Also known as: AL3818

  • DrugCisplatin or carboplatin

    Drug pages: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chemotherapy agent.Carboplatin: Day 1, AUC 5 mg/mL/min (max 750 mg), IV infusion; Cisplatin: Day 1, 75-80 mg/m², IV infusion.

  • Chemotherapy agent. Days 1-3, 100 mg/m², IV infusion.

  • RadiationThoracic Radiation Therapy

    External beam intensity-modulated radiotherapy (IMRT) targeting the primary thoracic tumor, ipsilateral hilum, and mediastinal lymph node stations (per LS-SCLC staging guidelines). Initiated with Cycle 1 of chemotherapy; IMRT, 60-70 Gy in 30-35 fractions (1.8-2.0 Gy/fraction, once daily); target volumes: primary tumor + lymph nodes delineated on post-chemotherapy CT, investigator-adjusted individually.

06

What researchers measure

Primary outcomes

  1. Investigator-Assessed Objective Response Rate

    According to RECIST 1.1 criteria, investigator assesses target lesion changes via imaging; calculates the proportion of subjects achieving complete response (CR) or partial response (PR)

    Time frame: Baseline at screening, after every 2 treatment cycles (each cycle is 21 days), end of treatment, up to disease progression, assessed up to approximately 24 months

Secondary outcomes

  1. Serious Adverse Event (SAE)

    Collect SAEs resulting in death, life-threatening condition, hospitalization, disability per CTCAE 5.0 and ICH-GCP, document and report

    Time frame: from date of first study drug administration, follow-up until resolution or stabilization, assessed up to approximately 24 months

  2. 6-Month Progression-Free Survival Rate

    Estimated proportion of subjects without progression and alive at 6 months after first treatment using Kaplan-Meier method

    Time frame: 6-month time point after first treatment, follow-up cutoff

  3. Immune-Related Adverse Event (irAE)

    Identify and grade organ-specific immune-related adverse events according to CTCAE 5.0 and irAE criteria

    Time frame: From date of first study drug administration through 90 days after the last dose of study drug; assessed at baseline, each cycle visit, and unscheduled visits for suspected irAEs; graded per CTCAE 5.0 and irAE-specific criteria.

  4. Progression-Free Survival (PFS)

    Time from first treatment to disease progression or death from any cause, whichever occurs first

    Time frame: From date of first study drug administration until the date of first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first; assessed up to 24 months (maximum follow-up period).

  5. 18-Month Overall Survival Rate

    Estimated proportion of alive subjects at 18 months after first treatment via Kaplan-Meier method

    Time frame: 18-month time point after first treatment, follow-up cutoff

  6. 12-Month Overall Survival Rate

    Estimated proportion of alive subjects at 12 months after first treatment using Kaplan-Meier method

    Time frame: 12-month time point after first treatment, follow-up cutoff

  7. 12-Month Progression-Free Survival Rate

    Estimated proportion of progression-free and alive subjects at 12 months via Kaplan-Meier method

    Time frame: 12-month time point after first treatment, follow-up cutoff

  8. Overall Survival (OS)

    Time from first study treatment to death from any cause; censored at last follow-up for alive subjects

    Time frame: From date of first study treatment to date of death from any cause or last follow-up, whichever occurs first, assessed up to approximately 24 months

  9. Disease Control Rate (DCR)

    According to RECIST 1.1, proportion of subjects achieving CR, PR, or stable disease (SD) in total enrolled population

    Time frame: Time Frame: Baseline and after every 2 treatment cycles (each cycle is 21 days), up to disease progression, death, or study withdrawal, whichever occurs first,assessed up to approximately 24 months

  10. Duration of Response (DOR)

    Time from first confirmed CR/PR to disease progression, death from any cause, or initiation of new antitumor therapy

    Time frame: From date of first confirmed objective response (CR/PR) until date of disease progression, death from any cause, or initiation of new antitumor therapy, whichever occurs first, assessed up to approximately 24 months

  11. Adverse Event (AE)

    Record all new or worsening unfavorable medical events, grade and calculate incidence according to CTCAE 5.0

    Time frame: From signing informed consent through study completion and safety follow-up, assessed up to approximately 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — The decision to share individual participant data (IPD) is currently undecided. This is an exploratory single-center clinical study, and IPD sharing will be re-evaluated after study completion and primary results analysis. Factors to be considered include the protection of participant privacy, compliance with ethical committee requirements, and the scientific validity of secondary research using the shared data. If IPD sharing is approved in the future, access will be provided in accordance with ClinicalTrials.gov guidelines and relevant regulatory requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 20, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2029
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07538258
Lead sponsor
Yayi He
Responsible party
Yayi He (Professor, Shanghai Pulmonary Hospital, Shanghai, China) — Sponsor-investigator
First posted
Apr 20, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Apr 20, 2026

Study contacts

Yayi He, MD
Contact
yayi.he@tongji.edu.cn
021-65115006-2393

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion